Page 114 - 《中国药房》2025年8期

[10] SYDNOR S，CHATTERJEE S，COONEY P，et al. Efficacy vitreal aflibercept with other therapies for diabetic macu‐
and safety of brolucizumab，aflibercept，and ranibizumab lar edema（DME）[J]. BMC Ophthalmol，2015，15：52.
for the treatment of patients with visual impairment due to [22] JIN E Z，LUO L，BAI Y J，et al. Comparative effective‐
diabetic macular oedema：a systematic review and network ness of intravitreal bevacizumab with or without triam‐
meta-analysis[J]. Diabetes Ther，2023，14（7）：1193-1216. cinolone acetonide for treatment of diabetic macular
[11] PATIL N S，MIHALACHE A，HATAMNEJAD A，et al. edema[J]. Ann Pharmacother，2015，49（4）：387-397.
Intravitreal steroids compared with anti-VEGF treatment [23] YANAGIDA Y，UETA T. Systemic safety of ranibizumab
for diabetic macular edema：a meta-analysis[J]. Ophthal‐ for diabetic macular edema：meta-analysis of randomized
mol Retina，2023，7（4）：289-299. trials[J]. Retina，2014，34（4）：629-635.
[12] CHI S C，KANG Y N，HUANG Y M. Efficacy and safety [24] LIU X D，ZHOU X D，WANG Z，et al. Comparison of in‐
profile of intravitreal dexamethasone implant versus anti‐ travitreal bevacizumab with macular photocoagulation for
vascular endothelial growth factor treatment in diabetic treatment of diabetic macular edema：a systemic review
macular edema：a systematic review and meta-analysis[J]. and meta-analysis[J]. Int J Ophthalmol，2014，7（6）：1048-
Sci Rep，2023，13：7428. 1055.
[13] CHEN J S，WANG H W，QIU W Q. Intravitreal anti- [25] CHEN G H，LI W S，TZEKOV R，et al. Ranibizumab
vascular endothelial growth factor，laser photocoagula‐ monotherapy or combined with laser versus laser mono‐
tion，or combined therapy for diabetic macular edema：a therapy for diabetic macular edema：a meta-analysis of
systematic review and network meta-analysis[J]. Front En‐ randomized controlled trials[J]. PLoS One，2014，9（12）：
docrinol，2023，14：1096105. e115797.
[14] SUN X Y，WEI W. Intravitreal conbercept with grid/focal [26] ZHANG Y，MA J L，MENG N N，et al. Comparison of in‐
photocoagulation for the treatment of diabetic macular travitreal triamcinolone acetonide with intravitreal bevaci‐
edema：a systematic review and meta-analysis[J]. J Oph‐ zumab for treatment of diabetic macular edema：a meta-
thalmol，2022，2022：2256779. analysis[J]. Curr Eye Res，2013，38（5）：578-587.
[15] ABDEL-MABOUD M，MENSHAWY E，BAHBAH E I， [27] ABOUAMMOH M A. Ranibizumab injection for diabetic
et al. Intravitreal bevacizumab versus intravitreal triam‐ macular edema：meta-analysis of systemic safety and system‐
cinolone for diabetic macular edema：systematic review， atic review[J]. Can J Ophthalmol，2013，48（4）：317-323.
meta-analysis and meta-regression[J]. PLoS One，2021，16 [28] WANG H Y，SUN X D，LIU K，et al. Intravitreal ranibi‐
（1）：e0245010. zumab（Lucentis）for the treatment of diabetic macular
[16] WEI Q Q，CHEN R，LOU Q Y，et al. Intravitreal cortico‐ edema：a systematic review and meta-analysis of rando-
steroid implant vs intravitreal ranibizumab for the treat‐ mized clinical control trials[J]. Curr Eye Res，2012，37
ment of macular edema：a meta-analysis of randomized （8）：661-670.
controlled trials[J]. Drug Des Devel Ther，2019，13： [29] FORTIN P，MINTZES B，INNES M. A systematic review
301-307. of intravitreal bevacizumab for the treatment of diabetic
[17] CUI L J，JIAO B T，HAN Q H. Effect of intravitreal anti- macular edema[J]. CADTH Technol Overv，2013，3（1）：
vascular growth factor agents with or without macular e3203.
photocoagulation on diabetic macular edema：a systematic [30] YILMAZ T，CORDERO-COMA M，GALLAGHER M J，
review and meta-analysis[J]. Diabetes Ther，2019，10（4）： et al. Systematic review of intravitreal bevacizumab injec‐
1283-1296. tion for treatment of primary diabetic macular oedema[J].
[18] XIAO K，WENG S J，LIANG S Z，et al. Effect of intravi- Acta Ophthalmol，2011，89（8）：709-717.
treal bevacizumab with or without macular photocoagu- [31] GOYAL S，LAVALLEY M，SUBRAMANIAN M L. Meta-
lation for diabetic macular edema：a meta-analysis[J]. Dia‐ analysis and review on the effect of bevacizumab in dia‐
betes Ther，2018，9（6）：2369-2381. betic macular edema[J]. Graefes Arch Clin Exp Ophthal‐
[19] HE Y，REN X J，HU B J，et al. A meta-analysis of the mol，2011，249（1）：15-27.
effect of a dexamethasone intravitreal implant versus intra‐ [32] ZHANG J F，ZHANG J X，ZHANG C Y，et al. Diabetic
vitreal anti-vascular endothelial growth factor treatment macular edema：current understanding，molecular mecha‐
for diabetic macular edema[J]. BMC Ophthalmol，2018， nisms and therapeutic implications[J]. Cells，2022，11
18（1）：121. （21）：3362.
[20] AVERY R L，GORDON G M. Systemic safety of pro‐ [33] LIBERSKI S，WICHROWSKA M，KOCIĘCKI J. Afliber‐
longed monthly anti-vascular endothelial growth factor cept versus faricimab in the treatment of neovascular age-
therapy for diabetic macular edema：a systematic review and related macular degeneration and diabetic macular edema：
meta-analysis[J]. JAMA Ophthalmol，2016，134（1）：21-29. a review[J]. Int J Mol Sci，2022，23（16）：9424.
[21] KOROBELNIK J F，KLEIJNEN J，LANG S H，et al. Sys‐ （收稿日期：2024-11-04 修回日期：2025-03-25）
tematic review and mixed treatment comparison of intra‐ （编辑：陈 宏）

· 1000 · China Pharmacy 2025 Vol. 36 No. 8 中国药房 2025年第36卷第8期